Coya Therapeutics Has Been Granted US FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics, Inc. announced that the US FDA has granted Fast Track Designation for COYA 302, an investigational biologic combination therapy with a dual mechanism of action, for the treatment of amyotrophic lateral sclerosis (ALS).